Breast cancer has four major subtypes on the basis of nuclear hormone receptors (ER and PR) and Her2 expression status, and these subtypes vary in their molecular profiles, prognosis and responsiveness to chemotherapy [24, 25]. This evidence concerns the gene ERBB2 and breast carcinoma.